Home / Current Issue / Paper 1723639
Invasive Ductal Carcinoma of the Breast: Molecular Evolution, Immune Escape, and Therapeutic Implications
Subject area: Biological & Medical Sciences · Area of research: Immunology
Abstract
Invasive ductal carcinoma (IDC) is the most common histological form of breast cancer and is characterized by marked molecular and immunological heterogeneity. Its progression from ductal carcinoma in situ (DCIS) to invasive disease is accompanied by disruption of the myoepithelial and basement-membrane barriers, extracellular-matrix remodelling, genomic evolution and changes in the tumour microenvironment (TME). Cancer immunoediting provides a useful framework for understanding this progression through elimination, equilibrium and escape. During escape, tumour cells and associated stromal and immune populations can reduce effective antitumour immunity through altered antigen presentation, immune-checkpoint signalling, immunosuppressive cytokines, metabolic reprogramming and recruitment of regulatory immune cells. Evidence from breast tumours demonstrates reduced cytotoxic T-cell activity and changes in immune-cell composition during the transition from DCIS to IDC. Genomic alterations involving TP53, PIK3CA and GATA3 contribute to subtype-specific tumour behaviour, while emerging studies implicate metabolic regulators such as acyl-CoA thioesterase 7 (ACOT7) in IDC biology and immune contexture. PD-L1 assessment illustrates the translational challenge of converting tumour immunobiology into reliable clinical biomarkers because assay platforms, scoring systems and specimen characteristics can influence classification. Therapeutically, immune-checkpoint blockade has become clinically important in selected breast-cancer populations, particularly early-stage triple-negative disease, while antibody–drug conjugates have expanded treatment options for HER2-low advanced breast cancer. This review synthesizes the immunological and molecular mechanisms underlying IDC progression, highlights diagnostic and therapeutic implications, and identifies research priorities relevant to resource-constrained settings.
Keywords
invasive ductal carcinoma; tumour microenvironment; immune escape; immunoediting; triple-negative breast cancer; immunotherapy; biomarkers.
References
[1] Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape. Curr Opin Immunol. 2014;27:16–25. ScienceDirect.
[2] Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331:1565–1570. Science.
[3] Gil Del Alcazar CR, Huh SJ, Ekram MB, et al. Immune escape in breast cancer during in situ to invasive carcinoma transition. Cancer Discov. 2017;7(10):1098–1115. AACR.
[4] Gil Del Alcazar CR, Alečković M, Polyak K. Immune escape during breast tumor progression. Cancer Immunol Res. 2020;8(4):422–427. AACR.
[5] Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70. Nature.
[6] Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346–352. Nature.
[7] Nik-Zainal S, Davies H, Staaf J, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016;551:47–55.
[8] Steven A, Seliger B. The role of immune escape and immune cell infiltration in breast cancer. Breast Care (Basel). 2018;13:16–21. Karger.
[9] Domschke C, Schneeweiss A, Stefanovic S, et al. Cellular immune responses and immune escape mechanisms in breast cancer: determinants of immunotherapy. Breast Care (Basel). 2016;11:206–212.
[10] Song CS, Quan Y, Shan Y, et al. Prognostic significance and regulatory role of ACOT7 in the tumor immune microenvironment of breast invasive ductal carcinoma: a multi-omics analysis. Front Immunol. 2026;17:1735908. Frontiers.
[11] Rugo HS, Loi S, Cortes J, et al. PD-L1 immunohistochemistry assay comparison in atezolizumab plus nab-paclitaxel-treated advanced triple-negative breast cancer. J Clin Oncol. 2021;39:2679–2689.
[12] Lee SE, Park HY, Lim SD, et al. Concordance of programmed death-ligand 1 expression between SP142 and 22C3/SP263 assays in triple-negative breast cancer. J Breast Cancer. 2020;23:303–313. Journal of Breast Cancer.
[13] Noske A, Wagner DC, Schwamborn K, Foersch S, Steiger K, Kiechle M, et al. Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer. Breast. 2021;60:238–244. ScienceDirect.
[14] Schmid P, Cortes J, Dent R, et al. Overall survival with pembrolizumab in early-stage triple-negative breast cancer. N Engl J Med. 2024;391:1981–1991. New England Journal of Medicine.
[15] Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9–20. New England Journal of Medicine.
How to cite this paper
@article{1723639,
author = {Nkiruka Rose Ukibe, Charles Chinedum Onyenekwe, Chidiogor Marigold Iheukwumere, Chinonso Colin Nwabueze},
title = {Invasive Ductal Carcinoma of the Breast: Molecular Evolution, Immune Escape, and Therapeutic Implications},
journal = {Iconic Research And Engineering Journals},
year = {2026},
volume = {10},
number = {4},
pages = {228-233},
issn = {2456-8880},
url = {https://www.irejournals.com/formatedpaper/1723639.pdf},
abstract = {Invasive ductal carcinoma (IDC) is the most common histological form of breast cancer and is characterized by marked molecular and immunological heterogeneity. Its progression from ductal carcinoma in situ (DCIS) to invasive disease is accompanied by disruption of the myoepithelial and basement-membrane barriers, extracellular-matrix remodelling, genomic evolution and changes in the tumour microenvironment (TME). Cancer immunoediting provides a useful framework for understanding this progression through elimination, equilibrium and escape. During escape, tumour cells and associated stromal and immune populations can reduce effective antitumour immunity through altered antigen presentation, immune-checkpoint signalling, immunosuppressive cytokines, metabolic reprogramming and recruitment of regulatory immune cells. Evidence from breast tumours demonstrates reduced cytotoxic T-cell activity and changes in immune-cell composition during the transition from DCIS to IDC. Genomic alterations involving TP53, PIK3CA and GATA3 contribute to subtype-specific tumour behaviour, while emerging studies implicate metabolic regulators such as acyl-CoA thioesterase 7 (ACOT7) in IDC biology and immune contexture. PD-L1 assessment illustrates the translational challenge of converting tumour immunobiology into reliable clinical biomarkers because assay platforms, scoring systems and specimen characteristics can influence classification. Therapeutically, immune-checkpoint blockade has become clinically important in selected breast-cancer populations, particularly early-stage triple-negative disease, while antibody–drug conjugates have expanded treatment options for HER2-low advanced breast cancer. This review synthesizes the immunological and molecular mechanisms underlying IDC progression, highlights diagnostic and therapeutic implications, and identifies research priorities relevant to resource-constrained settings.},
keywords = {invasive ductal carcinoma; tumour microenvironment; immune escape; immunoediting; triple-negative breast cancer; immunotherapy; biomarkers.},
month = {October},
}